🇺🇸 Symlin in United States

FDA authorised Symlin on 25 September 2007 · 98 US adverse-event reports

Marketing authorisation

FDA — authorised 25 September 2007

  • Application: NDA021332
  • Marketing authorisation holder: ASTRAZENECA AB
  • Indication: Manufacturing (CMC)
  • Status: approved

Read official source →

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Blood Glucose Increased — 20 reports (20.41%)
  2. Nausea — 15 reports (15.31%)
  3. Fatigue — 11 reports (11.22%)
  4. Dyspnoea — 9 reports (9.18%)
  5. Blood Glucose Decreased — 8 reports (8.16%)
  6. Diarrhoea — 8 reports (8.16%)
  7. Chest Pain — 7 reports (7.14%)
  8. Hypertension — 7 reports (7.14%)
  9. Weight Increased — 7 reports (7.14%)
  10. Dizziness — 6 reports (6.12%)

Source database →

Symlin in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Metabolic approved in United States

Frequently asked questions

Is Symlin approved in United States?

Yes. FDA authorised it on 25 September 2007.

Who is the marketing authorisation holder for Symlin in United States?

ASTRAZENECA AB holds the US marketing authorisation.